How Much Does Zepbound Cost in 2026, and What Are the Self-Pay Options?

Zepbound is the brand name for tirzepatide when prescribed for obesity or obstructive sleep apnea (OSA). The same molecule is sold as Mounjaro for type 2 diabetes. Zepbound targets two receptors simultaneously, GIP and GLP-1, which is why it is classified as a dual agonist rather than a simple GLP-1 receptor agonist like semaglutide (Wegovy, Ozempic). The FDA approved Zepbound for chronic weight management in November 2023 under NDA 217806, and added the OSA indication in December 2024.

The list price and the self-pay price are very different for Zepbound. The wholesale acquisition cost (WAC) is $1,086 per month for the KwikPen regardless of dose. Eli Lilly built LillyDirect, a direct-to-patient channel that sells single-dose vials and KwikPens at a reduced cash price without going through a pharmacy benefit manager (PBM). Through LillyDirect, self-pay patients can access Zepbound starting at $299 per month for the 2.5 mg dose. The savings card for commercially-insured patients brings the monthly copay to as low as $25, with up to $1,300 in annual savings, and expires December 31, 2026. The same molecule sold as Mounjaro for type 2 diabetes follows different insurance coverage rules. For semaglutide-based alternatives, compare Wegovy.

Medicare's coverage picture changed significantly in 2026. Medicare Part D covers Zepbound when prescribed for OSA. Beginning July 1, 2026, the CMS Medicare GLP-1 Bridge program extends Part D coverage to the KwikPen formulation for obesity-only diagnoses, with a capped monthly copay of $50 through December 31, 2027. For Medicaid, coverage depends entirely on the state: roughly 13 states covered GLP-1 medications for obesity under fee-for-service as of early 2026, and several others had paused or restricted coverage. Check whether Medicaid covers GLP-1 by state. No generic tirzepatide is approved or expected before approximately 2036 based on Eli Lilly's composition patent expiry.

What Zepbound Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same zepbound can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Zepbound is a self-administered weekly injection prescribed for outpatient use. It is not a drug typically billed during an inpatient hospital stay. The hospital pricing context for Zepbound is different from drugs like insulin: if tirzepatide does appear on a hospital bill, it is most likely as a medication continued during an admission rather than a primary treatment administered in the hospital. In that case, hospitals apply their standard drug markup on the acquisition cost.

The bigger affordability gap with Zepbound is between the list price ($1,086 per month) and the self-pay options. Most patients without commercial insurance that covers Zepbound face the full list price at retail pharmacies unless they access LillyDirect or another discount channel. Pharmacy benefit managers (PBMs) and insurers negotiate rebates that reduce what they actually pay, but those savings rarely flow through to the patient at the counter.

The LillyDirect self-pay channel is Lilly's direct response to this gap. By selling through its own pharmacy and bypassing the PBM layer, Lilly can offer single-dose vials and KwikPens at prices far below the WAC. The self-pay price cannot be combined with commercial insurance, and it cannot be used by Medicare or Medicaid beneficiaries. This channel is for cash-pay patients or those whose insurance does not cover Zepbound.

Patient Assistance Programs

Eli Lilly offers two programs to reduce Zepbound out-of-pocket costs. There is no traditional income-based patient assistance program (PAP) for Zepbound, unlike older generic drugs. The Lilly Cares Foundation covers Mounjaro (tirzepatide for type 2 diabetes) but does NOT cover Zepbound (the obesity or OSA indication). For uninsured Zepbound patients, LillyDirect self-pay is the primary affordability pathway.

Medicare Part D

Medicare Part D covers Zepbound when prescribed for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This OSA indication was FDA-approved in December 2024, which created a Medicare coverage pathway that did not previously exist. The OSA diagnosis code G47.33 must appear on the prescription and claim for coverage to apply. For the obesity-only indication, Part D plans are not required to cover Zepbound and most do not as of early 2026.

Starting July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a short-term demonstration program running through December 31, 2027. This program allows eligible Part D beneficiaries to access Zepbound KwikPen for an obesity diagnosis at a copayment of $50 per month. The single-dose vial formulation of Zepbound is excluded from the GLP-1 Bridge. Patients must meet eligibility requirements set by CMS and enroll through their Part D plan.

Under standard Part D in 2026, the annual out-of-pocket cap is $2,100. If your plan covers Zepbound for OSA, your total drug costs above the deductible count toward this cap. Once you hit $2,100, you pay $0 for covered drugs for the rest of the year. This protection applies to patients who need ongoing monthly therapy. Medicare beneficiaries cannot use LillyDirect self-pay or the Zepbound Savings Card as supplements to Medicare.

Common Zepbound Billing Errors

Zepbound billing errors arise most often when the diagnosis code, formulary tier, or coverage indication is applied incorrectly. These are the most common issues to watch for:

• Claim denied as obesity-only when OSA diagnosis is also present: If you have both obesity and OSA, the OSA diagnosis code (G47.33 for obstructive sleep apnea) must appear on the prescription and claim. Missing it causes a denial that should not happen.
• Billed as Mounjaro (diabetes) instead of Zepbound (obesity/OSA): Tirzepatide is sold under two brand names. Mounjaro is for type 2 diabetes; Zepbound is for obesity and OSA. Billing the wrong brand name can affect prior authorization approval and formulary tier placement.
• LillyDirect price applied to an insured patient or vice versa: The LillyDirect self-pay price ($299 to $449 per month) cannot be combined with insurance. Patients with active coverage who attempt to use the self-pay price will not be able to; they must use the savings card or their plan copay instead.
• Prior authorization denied for missing documentation: Most commercial plans require prior authorization (PA) for Zepbound. Common reasons for PA denial include missing BMI documentation, missing comorbidity records, or failure to document prior weight management attempts.
• Medicare GLP-1 Bridge KwikPen only: The $50 per month GLP-1 Bridge copay applies only to the Zepbound KwikPen formulation. If the prescription is written for single-dose vials, it will not be processed under the GLP-1 Bridge program.
• Savings card charged after expiry date: The Zepbound Savings Card for commercially-insured patients expires December 31, 2026. Claims processed in 2027 or after will not receive the $25 copay unless a new savings program is issued by Lilly.

Frequently Asked Questions